Cannabix Technologies Inc. BLO

Company Overview

Cannabix Technologies Inc. is a Canadian technology company focused on the development of non-invasive drug and alcohol screening technologies, with a primary emphasis on marijuana breath detection devices. The company operates within the broader sectors of public safety technology, law enforcement screening, workplace testing, and roadside impairment detection. Its core objective is to commercialize portable breathalyzer systems capable of detecting delta-9 tetrahydrocannabinol (THC) and alcohol impairment through breath samples rather than traditional blood, urine, or saliva testing methods.

The company’s primary business activities center on research, prototype development, intellectual property generation, and regulatory advancement related to cannabis and alcohol breath-testing technologies. Cannabix has positioned itself as a specialized developer in a niche market driven by cannabis legalization trends, workplace safety requirements, and increasing demand for rapid roadside impairment screening. Public filings and corporate disclosures indicate that the company evolved from earlier-stage technology initiatives into a dedicated breath diagnostics developer focused on law enforcement and industrial safety applications. Data regarding large-scale commercial deployment or material recurring revenue remains limited based on available public sources.

Business Operations

Cannabix conducts operations primarily through technology development, patent acquisition, engineering partnerships, and prototype testing initiatives. Its principal operating focus includes the development of the THC Breath Analyzer platform and related alcohol breath screening technologies. The company has also referenced development initiatives involving contactless alcohol screening and autonomous impairment detection systems intended for transportation hubs, workplaces, and law enforcement settings. Revenue generation historically has been limited and largely associated with capital market financing activities rather than mature product commercialization, according to publicly available financial disclosures.

Operations are centered primarily in Canada, with technology development and intellectual property activities supported through collaborations with engineering firms, scientific advisors, and specialized manufacturing partners. Cannabix has disclosed involvement with subsidiary entities including Cannabix Breathalyzer Inc. and related intellectual property holdings tied to breath diagnostics technologies. The company’s strategic assets include patent applications, proprietary detection methodologies, and prototype development programs targeting portable and fixed-site screening systems. Publicly available information does not confirm material joint ventures or large-scale commercial manufacturing agreements as of recent filings.

Strategic Position & Investments

Cannabix’s strategic direction is focused on advancing commercialization readiness for cannabis breath detection technologies amid evolving global cannabis regulation frameworks. Growth initiatives have included continued investment in research and development, prototype refinement, sensor accuracy improvements, and validation studies intended to support future regulatory acceptance and market adoption. The company has also pursued intellectual property expansion through patent filings related to breath collection, detection systems, and impairment screening technologies.

The company has emphasized emerging sectors including roadside drug testing, workplace impairment monitoring, and contactless alcohol screening systems. Cannabix has publicly referenced development programs involving autonomous alcohol screening devices designed for institutional and transportation applications. While the company has pursued technology-focused investments and development partnerships, publicly verified information regarding significant acquisitions or large-scale strategic investments remains limited. Data inconclusive based on available public sources regarding any major commercial licensing agreements or substantial revenue-generating portfolio companies.

Geographic Footprint

Cannabix Technologies Inc. is headquartered in Canada and is publicly traded on the Canadian Securities Exchange (CSE) under the symbol BLO, with additional quotation on U.S. over-the-counter markets. Its operational footprint is concentrated primarily in North America, particularly within Canadian technology development and regulatory environments associated with cannabis legalization and impaired driving enforcement.

The company’s market focus extends internationally through the potential applicability of its screening technologies in jurisdictions adopting legalized or regulated cannabis frameworks. Corporate materials and investor disclosures indicate strategic interest in law enforcement, transportation safety, and workplace compliance markets across North America, with broader relevance to international public safety sectors. However, publicly available filings do not confirm significant foreign operating subsidiaries, international manufacturing facilities, or large-scale overseas commercial operations.

Leadership & Governance

Cannabix Technologies Inc. is overseen by a management team and board focused on technology commercialization, public safety applications, and capital market development. Leadership communications have consistently emphasized advancing scientifically validated breath testing technologies intended to support law enforcement efficiency, workplace safety, and regulatory compliance in legalized cannabis environments.

Key executives and leadership figures identified in public filings and corporate disclosures include:

• Rav Mlait – Chief Executive Officer
• Kal Malhi – Director
• Richard Russell – Chief Financial Officer
• Dr. Raj Attariwala – Scientific Advisor
• Dr. Bruce Goldberger – Scientific Advisor

The company’s governance approach appears centered on maintaining technology development momentum, intellectual property expansion, and regulatory credibility through scientific advisory participation and ongoing prototype validation efforts. Public filings, including SEDAR+ disclosures and company financial statements, remain the primary verified sources regarding executive leadership and governance structure.